These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24900456)

  • 1. Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye.
    Zhong M; Gadek TR; Bui M; Shen W; Burnier J; Barr KJ; Hanan EJ; Oslob JD; Yu CH; Zhu J; Arkin MR; Evanchik MJ; Flanagan WM; Hoch U; Hyde J; Prabhu S; Silverman JA; Wright J
    ACS Med Chem Lett; 2012 Mar; 3(3):203-6. PubMed ID: 24900456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye Disease.
    Pflugfelder SC; Stern M; Zhang S; Shojaei A
    J Ocul Pharmacol Ther; 2017; 33(1):5-12. PubMed ID: 27906544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjögrens syndrome-like MRL/lpr mice.
    Gao J; Morgan G; Tieu D; Schwalb TA; Luo JY; Wheeler LA; Stern ME
    Exp Eye Res; 2004 Apr; 78(4):823-35. PubMed ID: 15037117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and LFA-1/ICAM-1 antagonist activity evaluation of Lifitegrast analogues.
    Du G; Du W; An Y; Wang M; Hao F; Tong X; Gong Q; He X; Jiang H; He W; Zheng M; Zhang D
    Med Chem Res; 2022; 31(4):555-579. PubMed ID: 35194364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists.
    Zhong M; Shen W; Barr KJ; Arbitrario JP; Arkin MR; Bui M; Chen T; Cunningham BC; Evanchik MJ; Hanan EJ; Hoch U; Huen K; Hyde J; Kumer JL; Lac T; Lawrence CE; Martell JR; Oslob JD; Paulvannan K; Prabhu S; Silverman JA; Wright J; Yu CH; Zhu J; Flanagan WM
    Bioorg Med Chem Lett; 2010 Sep; 20(17):5269-73. PubMed ID: 20655213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lifitegrast: First LFA-1/ICAM-1 antagonist for treatment of dry eye disease.
    Paton DM
    Drugs Today (Barc); 2016 Sep; 52(9):485-493. PubMed ID: 27883115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [TOPICAL ANTI-INFLAMMATORY AGENTS FOR DRY EYE DISEASE].
    Erdinest N; Solomon A
    Harefuah; 2019 Feb; 158(2):130-135. PubMed ID: 30779493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists.
    Zhong M; Hanan EJ; Shen W; Bui M; Arkin MR; Barr KJ; Evanchik MJ; Hoch U; Hyde J; Martell JR; Oslob JD; Paulvannan K; Prabhu S; Silverman JA; Wright J; Yu CH; Zhu J; Flanagan WM
    Bioorg Med Chem Lett; 2011 Jan; 21(1):307-10. PubMed ID: 21109434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Multivalent ICAM-1 Binding Nanoparticle which Inhibits ICAM-1 and LFA-1 Interaction Represents a New Tool for the Investigation of Autoimmune-Mediated Dry Eye.
    Hsueh PY; Ju Y; Vega A; Edman MC; MacKay JA; Hamm-Alvarez SF
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.
    Keating GM
    Drugs; 2017 Feb; 77(2):201-208. PubMed ID: 28058622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors.
    Anderson ME; Siahaan TJ
    Peptides; 2003 Mar; 24(3):487-501. PubMed ID: 12732350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease.
    Semba CP; Gadek TR
    Clin Ophthalmol; 2016; 10():1083-94. PubMed ID: 27354762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs.
    Murphy CJ; Bentley E; Miller PE; McIntyre K; Leatherberry G; Dubielzig R; Giuliano E; Moore CP; Phillips TE; Smith PB; Prescott E; Miller JM; Thomas P; Scagliotti R; Esson D; Gadek T; O'Neill CA
    Invest Ophthalmol Vis Sci; 2011 May; 52(6):3174-80. PubMed ID: 21330663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intercellular adhesion molecule-1 (ICAM-1) and leukocyte function-associated antigen-1 (LFA-1) expression in human epiretinal membranes.
    Heidenkummer HP; Kampik A
    Graefes Arch Clin Exp Ophthalmol; 1992; 230(5):483-7. PubMed ID: 1355751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule LFA-1 antagonists compete with an anti-LFA-1 monoclonal antibody for binding to the CD11a I domain: development of a flow-cytometry-based receptor occupancy assay.
    Woska JR; Last-Barney K; Rothlein R; Kroe RR; Reilly PL; Jeanfavre DD; Mainolfi EA; Kelly TA; Caviness GO; Fogal SE; Panzenbeck MJ; Kishimoto TK; Giblin PA
    J Immunol Methods; 2003 Jun; 277(1-2):101-15. PubMed ID: 12799043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1).
    Marlin SD; Springer TA
    Cell; 1987 Dec; 51(5):813-9. PubMed ID: 3315233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ICAM, an adhesion ligand of LFA-1, is homologous to the neural cell adhesion molecule NCAM.
    Simmons D; Makgoba MW; Seed B
    Nature; 1988 Feb; 331(6157):624-7. PubMed ID: 3340213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of LFA-1, ICAM-1, VLA-4 and VCAM-1 in lymphocyte migration across retinal pigment epithelial monolayers in vitro.
    Devine L; Lightman SL; Greenwood J
    Immunology; 1996 Jul; 88(3):456-62. PubMed ID: 8774365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A peptide derived from LFA-1 protein that modulates T-cell adhesion binds to soluble ICAM-1 protein.
    Jois SD; Teruna TJ
    J Biomol Struct Dyn; 2003 Apr; 20(5):635-44. PubMed ID: 12643766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LFA-1 and ICAM-1 expression induced during melanoma-endothelial cell co-culture favors the transendothelial migration of melanoma cell lines in vitro.
    Ghislin S; Obino D; Middendorp S; Boggetto N; Alcaide-Loridan C; Deshayes F
    BMC Cancer; 2012 Oct; 12():455. PubMed ID: 23039186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.